Navigation Links
Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
Date:1/7/2008

HONOLULU, Jan. 7 /PRNewswire/ -- Hawaii Biotech, Inc. announced today that it has been notified by the United States Food and Drug Administration (FDA) that it may proceed to initiate a 24 patient safety study in healthy human volunteers with its recombinant, subunit West Nile vaccine. The trial will be conducted at a single site in Hawaii, which the company currently expects to start in April 2008, pending successful completion of financing sufficient funding to complete the trial. Depending on the actual start date, results of the trial may be available by the end of 2008.

HBI develops subunit vaccine candidates that have been shown to elicit protective immune responses in animal efficacy models for diseases such as West Nile, dengue, influenza, Ebola, malaria and tick-borne encephalitis.

"The West Nile vaccine will be the first candidate to enter clinical trials for Hawaii Biotech. This is a substantial milestone for the company as it is a novel vaccine candidate with which the FDA has had little experience. Receiving this notification from the FDA that we may proceed to human clinical trials is the first step in proving our technology in a clinical setting and to the scientific community," said Dr. Carolyn Weeks-Levy, President and CEO of HBI.

Currently there is no vaccine for the prevention of West Nile disease in humans; a disease that has caused over 25,000 cases of disease and over 1000 deaths since the virus was introduced in the U.S. in 1999.

About Hawaii Biotech, Inc.

Hawaii Biotech is a privately held biotechnology company focused on the research and development of prophylactic vaccines for infectious diseases. Hawaii Biotech has developed a proprietary protein production platform that has application to the production of proteins for use as antigens in infectious disease vaccines. In addition, to its work on a dengue vaccine, the company is also developing vaccines for West Nile virus and seasonal influenza. Hawaii Biotech is headquartered in Honolulu, Hawaii. For more information please visit: http://www.hibiotech.com.


'/>"/>
SOURCE Hawaii Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
2. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
3. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
4. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
10. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
11. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 ... bedient dringenden Bedarf zur ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung ... zu sein. Ein erstes Projekt wird die Entwicklung ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):